Invicro and icometrix Announce a Unique Partnership to Provide an Automated Workflow for Imaging Core Lab Services and Advanced Informatics to Pharmaceutical and Biotechnology Sponsors Worldwide.

BOSTON & LEUVEN, Belgium–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/biomarkers?src=hash” target=”_blank”gt;#biomarkerslt;/agt;–Invicro LLC, a Konica Minolta company and icometrix jointly
announced a partnership that will seamlessly offer the world’s most
comprehensive breadth of imaging core lab services combined with the
most robust FDA-cleared MRI informatics capabilities through automated
workflows. Pharmaceutical sponsors will experience one point of contact
for study site set-up and training which will harmonize with a single
platform for data management, sharing and analytics.

Invicro is a leading provider of quantitative imaging biomarkers, core
lab services and software solutions for research and drug development,
and Belgium based icometrix is the world leader in software
solutions to obtain clinically meaningful data from brain MRI and CT
scans. This unique partnership combines streamlined core lab processes
and advanced imaging technologies with FDA-cleared software for clinical
trials. This collaboration will deliver a more efficient, flexible
solution to help expedite drug discovery and development and provide
better insights in disease diagnostics.

“We are excited to partner with icometrix to jointly offer global
imaging core lab services and advanced analytics capabilities, resulting
in workflows with highly-reliable and consistent data outcomes,”
said Dr. Jacob Hesterman, Founding Partner and Head of R&D at Invicro.
“Our Pharma and Biotech sponsors will benefit from the combination of
established core lab operational excellence and analytics with robust,
cutting-edge analysis tools in disease areas like Multiple Sclerosis,
Alzheimer’s disease and Traumatic Brain Injury, enabling statistically
powerful quantitation and fast, accurate decision-making.”

“We started icometrix to help patients with neurological
disorders by providing more objective and consistent reading of brain
scans in the clinical setting,” said Dr. Annemie Ribbens, VP Clinical
Trials of icometrix. “As there is a huge interest to use our FDA
cleared imaging measures in clinical trials and real-world studies, we
are excited to partner with a global leader in this field.”

About icometrix
icometrix (Leuven, Belgium;
Chicago, IL, USA) is the world leader in software solutions to obtain
clinically meaningful data from brain MRI and CT scans. The fully
automated icobrain software is FDA cleared, and today, it is part
of routine clinical practice in hospitals in Europe, Japan, India,
Canada, Brazil and Australia. Furthermore, icometrix works with
the largest health tech and pharmaceutical companies on the evaluation
of trials of drugs for neurological diseases.

About Invicro
Headquartered in Boston, MA, Invicro was
founded in 2008 with the mission of improving the role and function of
imaging in translational drug discovery and development across all
therapeutic areas. Today, Invicro’s multi-disciplinary team provides
solutions to pharmaceutical and biotech companies across all stages of
the drug development pipeline (Phase 0-IV), all imaging modalities and
all therapeutic areas, including neurology, oncology, cardiology, and
pulmonary. Invicro’s quantitative biomarker services, advanced analytics
and AI tools, and clinical operational services are backed by Invicro’s
industry-leading software informatics platforms, VivoQuant®
and iPACS®.

As part of the Konica Minolta precision medicine organization and with
their sister company Ambry Genetics, Invicro develops and leverages the
latest approaches in quantitative biomarkers including imaging,
quantitative pathology and genomics. For more information, visit www.invicro.com.

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer’s most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow’s issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/.

Contacts

Amanda Harrell
VP, Global Marketing
[email protected]

Invicro and icometrix Announce a Unique Partnership to Provide an Automated Workflow for Imaging Core Lab Services and Advanced Informatics to Pharmaceutical and Biotechnology Sponsors Worldwide.

BOSTON & LEUVEN, Belgium–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/biomarkers?src=hash” target=”_blank”gt;#biomarkerslt;/agt;–Invicro LLC, a Konica Minolta company and icometrix jointly
announced a partnership that will seamlessly offer the world’s most
comprehensive breadth of imaging core lab services combined with the
most robust FDA-cleared MRI informatics capabilities through automated
workflows. Pharmaceutical sponsors will experience one point of contact
for study site set-up and training which will harmonize with a single
platform for data management, sharing and analytics.

Invicro is a leading provider of quantitative imaging biomarkers, core
lab services and software solutions for research and drug development,
and Belgium based icometrix is the world leader in software
solutions to obtain clinically meaningful data from brain MRI and CT
scans. This unique partnership combines streamlined core lab processes
and advanced imaging technologies with FDA-cleared software for clinical
trials. This collaboration will deliver a more efficient, flexible
solution to help expedite drug discovery and development and provide
better insights in disease diagnostics.

“We are excited to partner with icometrix to jointly offer global
imaging core lab services and advanced analytics capabilities, resulting
in workflows with highly-reliable and consistent data outcomes,”
said Dr. Jacob Hesterman, Founding Partner and Head of R&D at Invicro.
“Our Pharma and Biotech sponsors will benefit from the combination of
established core lab operational excellence and analytics with robust,
cutting-edge analysis tools in disease areas like Multiple Sclerosis,
Alzheimer’s disease and Traumatic Brain Injury, enabling statistically
powerful quantitation and fast, accurate decision-making.”

“We started icometrix to help patients with neurological
disorders by providing more objective and consistent reading of brain
scans in the clinical setting,” said Dr. Annemie Ribbens, VP Clinical
Trials of icometrix. “As there is a huge interest to use our FDA
cleared imaging measures in clinical trials and real-world studies, we
are excited to partner with a global leader in this field.”

About icometrix
icometrix (Leuven, Belgium;
Chicago, IL, USA) is the world leader in software solutions to obtain
clinically meaningful data from brain MRI and CT scans. The fully
automated icobrain software is FDA cleared, and today, it is part
of routine clinical practice in hospitals in Europe, Japan, India,
Canada, Brazil and Australia. Furthermore, icometrix works with
the largest health tech and pharmaceutical companies on the evaluation
of trials of drugs for neurological diseases.

About Invicro
Headquartered in Boston, MA, Invicro was
founded in 2008 with the mission of improving the role and function of
imaging in translational drug discovery and development across all
therapeutic areas. Today, Invicro’s multi-disciplinary team provides
solutions to pharmaceutical and biotech companies across all stages of
the drug development pipeline (Phase 0-IV), all imaging modalities and
all therapeutic areas, including neurology, oncology, cardiology, and
pulmonary. Invicro’s quantitative biomarker services, advanced analytics
and AI tools, and clinical operational services are backed by Invicro’s
industry-leading software informatics platforms, VivoQuant®
and iPACS®.

As part of the Konica Minolta precision medicine organization and with
their sister company Ambry Genetics, Invicro develops and leverages the
latest approaches in quantitative biomarkers including imaging,
quantitative pathology and genomics. For more information, visit www.invicro.com.

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer’s most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow’s issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/.

Contacts

Amanda Harrell
VP, Global Marketing
[email protected]

error: Content is protected !!